

EphMRA Committee Telecon: Minutes & Actions
12 November 2018

Participants:	Sarah May Hall	Georgina Butcher – Chair
	Xander Raijmakers	Roni DasGupta
	Mattias Blomgren	Anne Beatrice Clidassou
	Alex Adams	Chloe Simmons
	Jessica Santos	Bernadette Rogers
	Christine Mai	
Apologies	Matteo Cappai	Piergiorgio Rossi
	Karen Giorgio Vigo	

Please kindly remember that all EC discussions should remain confidential

MINUTES & ACTIONS

1	<p>Follow ups from September minutes</p> <p>Working relationship with EFAMRO now moving forward:</p> <ul style="list-style-type: none"> - Ethics news update - Short term and medium term objectives identified - Need to increase our communication and give a positive perception that EphMRA is up to date with ethics news
2	<p>GDPR</p> <p>A table summarising observation and/or listening to market research interviews was felt to be a useful idea but the description as to why/when to name is potentially confusing.</p> <p>It raised questions within the EG and this highlighted the potential to increase confusion around the role and naming of the Data Controller (particularly as Pharma companies might potentially have differing legal opinion on defining DC).</p> <p>It was agreed not to action the summary table on GDPR for the time being and to re-visit it during first half of 2019 to more clearly define the purpose and how it might be used by Members or the wider healthcare MR community.</p>
3	<p>US Sunshine Act</p> <p>It was agreed that Bernadette and Roni will liaise with US Insights Association on how EphMRA can communicate guidance on the US Sunshine Act for US and international healthcare MR.</p> <p>Jessica commented that some Pharma companies interpret differently and require names to include in their transparency publication. How can EphMRA support Insight and global MR to better understand the US transparency requirements for MR, i.e. provided client does not know identity of respondent there is no requirement to publish name/fee?</p> <p>ACTION BR/RDG follow up identify how EphMRA can support. Discuss possible actions Jan-19 call</p>

4	<p>AE reporting – patients/consumers</p> <p>The September telecon agreed in principle to apply ABPIA/BHBIA change for wider EU patients/consumers AE reporting. Pharma EG members feedback confirmed PV accept the change should apply to EU to provide quality of AE reporting in this area.</p> <p>BR/GB draft statement on change to apply to EU countries and circulate to EG for final comment by 23 Nov. EphMRA to announce change by 30 November latest.</p> <p>ACTION: BR/GB draft statement and circulate.</p>
5	<p>Other topics</p> <p>Articles (comms) to be published in other countries – BR to follow up with EFAMRO</p> <p>Wider Data Protection review – other countries updating privacy laws include Brazil, China, Thailand, etc – EG share links, news etc on proposed changes to discuss implications in Jan-19 call.</p> <p>ACTION: Wider Data Protection review.</p> <p>Additional DP issue: conflicting country regulation prohibiting identity of end client to be revealed includes Spain and Denmark – EG to feedback with examples, share regulation. Jan-19 discuss ideas / solutions to address conflicts. Bernadette is following these issues up with EFAMRO.</p>